Company
Headquarters: Beijing, China
Employees: 907
CN¥8.17 Billion
CNY as of July 1, 2025
US$1.14 Billion
| Company | Market Cap (USD) |
|---|---|
| Thermo Fisher Scientific | $162.07 B |
| Danaher | $144.92 B |
| Siemens Healthineers AG | $64.17 B |
| Lonza Group Ltd | $49.67 B |
| IDEXX Laboratories, Inc. | $43.99 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $699.59 B |
| Johnson & Johnson | $374.29 B |
| AbbVie | $336.94 B |
| Novo Nordisk | $309.91 B |
| UnitedHealth Group | $279.90 B |
Beijing Strong Biotechnologies, Inc. provides in-vitro diagnostics products and services in the People's Republic of China and internationally. It offers clinical biochemistry products, such as reagents and automatic biochemistry analyzers; coagulation products, including reagents and automated coagulation analyzers; and serology products comprising blood type test cards and automated blood grouping analyzers. The company was founded in 2001 and is headquartered in Beijing, the People's Republic of China.
| Last Financial Reports Date | March 31, 2025 |
| Revenue TTM | CN¥1.58 B |
| EBITDA | CN¥632.5 M |
| Gross Profit TTM | CN¥1.25 B |
| Profit Margin | 31.25% |
| Operating Margin | 33.46% |
| Quarterly Revenue Growth | -18.80% |
Beijing Strong Biotechnologies, Inc. has the following listings and related stock indices.
Stock: SZSE: 300406 wb_incandescent